NO20060764L - Bindingskonstruksjoner og fregangsmater for andvendelse derav - Google Patents
Bindingskonstruksjoner og fregangsmater for andvendelse deravInfo
- Publication number
- NO20060764L NO20060764L NO20060764A NO20060764A NO20060764L NO 20060764 L NO20060764 L NO 20060764L NO 20060764 A NO20060764 A NO 20060764A NO 20060764 A NO20060764 A NO 20060764A NO 20060764 L NO20060764 L NO 20060764L
- Authority
- NO
- Norway
- Prior art keywords
- fusion proteins
- binding domain
- ige
- immunoglobulin
- freestanding
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/627,556 US7829084B2 (en) | 2001-01-17 | 2003-07-26 | Binding constructs and methods for use thereof |
| PCT/US2003/041600 WO2005017148A1 (en) | 2003-07-26 | 2003-12-24 | Binding constructs and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060764L true NO20060764L (no) | 2006-04-20 |
Family
ID=34193490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060764A NO20060764L (no) | 2003-07-26 | 2006-02-17 | Bindingskonstruksjoner og fregangsmater for andvendelse derav |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7829084B2 (is) |
| EP (1) | EP1654358B1 (is) |
| JP (2) | JP4904443B2 (is) |
| KR (1) | KR101163240B1 (is) |
| CN (2) | CN102643344A (is) |
| AP (1) | AP2006003527A0 (is) |
| AT (1) | ATE525399T1 (is) |
| AU (1) | AU2003300092B2 (is) |
| BR (1) | BR0318417A (is) |
| CA (1) | CA2533921A1 (is) |
| CR (1) | CR8257A (is) |
| EA (1) | EA200600313A1 (is) |
| ES (1) | ES2376751T3 (is) |
| HR (1) | HRP20060074A2 (is) |
| IL (1) | IL173322A0 (is) |
| IS (1) | IS8305A (is) |
| NO (1) | NO20060764L (is) |
| NZ (1) | NZ545316A (is) |
| PL (1) | PL381765A1 (is) |
| RS (1) | RS20060055A (is) |
| TN (1) | TNSN06029A1 (is) |
| UA (1) | UA90999C2 (is) |
| WO (1) | WO2005017148A1 (is) |
| ZA (1) | ZA200601653B (is) |
Families Citing this family (375)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308981T3 (es) * | 1999-04-09 | 2008-12-16 | Universitat Zurich | Metodo para la estabilizacion de las inmunoglobulinas hibridas o fragmentos de inmunoglobulina y fragmentos anti-egp-2-scfv estabilizado. |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| HUE033533T2 (en) | 2003-04-30 | 2017-12-28 | Universität Zuerich | A method of treating cancer using immunotoxin |
| EP2960251A1 (en) | 2003-05-09 | 2015-12-30 | Duke University | CD20-specific antibodies and methods of employing same |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| MXPA05007210A (es) | 2003-11-13 | 2006-02-10 | Hanmi Pharm Ind Co Ltd | Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo. |
| MX2007001638A (es) * | 2004-08-11 | 2009-02-12 | Trubion Pharmaceuticals Inc | Proteinas de fusion del dominio de unión. |
| JP5303146B2 (ja) | 2004-10-06 | 2013-10-02 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法 |
| US8137907B2 (en) | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
| AU2006214384A1 (en) | 2005-02-14 | 2006-08-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of IL-17F in diagnosis and therapy of airway inflammation |
| RU2007129263A (ru) * | 2005-02-14 | 2009-03-20 | Вайет (Us) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| EP1879917A2 (en) * | 2005-04-29 | 2008-01-23 | Wyeth | Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same |
| CA2608770C (en) | 2005-05-18 | 2017-05-30 | Ablynx Nv | Improved nanobodies against tumor necrosis factor-alpha |
| EP1896587A2 (en) | 2005-05-31 | 2008-03-12 | Cold Spring Harbor Laboratory | METHODS FOR PRODUCING MICRORNAs |
| CA2610960A1 (en) * | 2005-06-06 | 2006-12-14 | Wyeth | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases |
| KR101514463B1 (ko) | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| US20070014776A1 (en) * | 2005-06-09 | 2007-01-18 | Gimeno Ruth E | Identification of adiponutrin-related proteins as esterases and methods of use for the same |
| SI2314623T1 (sl) | 2005-06-21 | 2012-11-30 | Xoma Technology Ltd | IL beta vezavna protitelesa in njihovi fragmenti |
| CN101268101A (zh) * | 2005-07-07 | 2008-09-17 | 科利制药集团公司 | 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗 |
| CN101273053A (zh) * | 2005-07-13 | 2008-09-24 | 安进芒廷维尤公司 | Il-6结合蛋白 |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| BRPI0614183A2 (pt) | 2005-07-25 | 2011-03-15 | Trubion Pharmaceuticals Inc | uso de dose única de moléculas de ligação especìficas para cd20 |
| WO2007014278A2 (en) * | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| ES2659114T3 (es) * | 2005-08-19 | 2018-03-13 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8 |
| EP1945240B1 (en) | 2005-09-16 | 2016-12-28 | Raptor Pharmaceutical Inc | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
| KR20080090406A (ko) * | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS |
| WO2007109749A2 (en) * | 2006-03-21 | 2007-09-27 | Wyeth | Methods for preventing and treating amyloidogenic diseases |
| CA2648849A1 (en) * | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals, Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
| BRPI0709623A2 (pt) * | 2006-04-19 | 2011-07-19 | Wyeth Corp | polinucleotìdeo inibitório, molécula de dna isolado, célula hospedeira, microorganismo, animal transgênico não humano, planta transgênica, kit, e, método para regular de modo negativo a expressão de um transgene por uma célula hospedeira |
| CN101472947A (zh) * | 2006-04-21 | 2009-07-01 | 惠氏公司 | 用于高通量筛选细胞系的方法 |
| ES2469676T3 (es) * | 2006-05-25 | 2014-06-18 | Bayer Intellectual Property Gmbh | Complejos moleculares dim�ricos |
| US20070274987A1 (en) * | 2006-05-25 | 2007-11-29 | Valerie Clerin | Expression of the cysteine protease legumain in vascular and inflammatory diseases |
| AU2016231617B2 (en) * | 2006-06-12 | 2018-08-23 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| US20080027001A1 (en) * | 2006-07-07 | 2008-01-31 | Andrew Wood | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| WO2008011571A1 (en) * | 2006-07-21 | 2008-01-24 | Amgen Inc. | Polypeptides with reduced susceptibility to oxidation and methods of making |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EP2420252A1 (en) | 2006-08-04 | 2012-02-22 | Novartis AG | EPHB3-specific antibody and uses thereof |
| AR064801A1 (es) * | 2006-08-18 | 2009-04-29 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| EP2059258B1 (en) * | 2006-09-08 | 2019-11-13 | Wyeth LLC | Arginine wash in protein purification using affinity chromatography |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20080132688A1 (en) * | 2006-09-22 | 2008-06-05 | Amgen Inc. | Methods for Removing Viral Contaminants During Protein Purification |
| CN101522219A (zh) * | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
| US7846434B2 (en) * | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| BRPI0717601A2 (pt) * | 2006-10-24 | 2013-10-22 | Trubion Pharmaceuticals Inc | Materiais e métodos para imunoglicoproteínas melhoradas |
| WO2008070780A1 (en) | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonist antibodies against ephb3 |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| AU2007336242B2 (en) | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| MX2009006709A (es) | 2006-12-20 | 2009-07-02 | Xoma Technology Ltd | Tratamiento de enfermedades relacionadas con il-1beta. |
| US20100040614A1 (en) * | 2006-12-27 | 2010-02-18 | Rafi Ahmed | Compositions and methods for the treatment of infections and tumors |
| EP2111412A2 (en) * | 2007-02-02 | 2009-10-28 | Amgen, Inc | Hepcidin and hepcidin antibodies |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| JP5837747B2 (ja) * | 2007-05-17 | 2015-12-24 | ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 組換えタンパク質を工業規模で製造する方法 |
| WO2008150485A2 (en) * | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| JP5577243B2 (ja) * | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
| EP2170951A2 (en) * | 2007-05-31 | 2010-04-07 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| WO2009023562A2 (en) * | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| SI2769729T1 (sl) | 2007-09-04 | 2019-06-28 | Compugen Ltd. | Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil |
| CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
| CN103172750B (zh) * | 2007-11-01 | 2014-12-10 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
| AU2014250683B2 (en) * | 2007-11-01 | 2015-11-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| EP2391650B1 (en) | 2007-12-20 | 2014-10-15 | Xoma (Us) Llc | Methods for the treatment of gout |
| WO2009086072A2 (en) | 2007-12-21 | 2009-07-09 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
| CA2709354C (en) | 2007-12-21 | 2014-06-17 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| JP5701064B2 (ja) | 2008-01-25 | 2015-04-15 | アムジエン・インコーポレーテツド | フェロポーチン抗体およびその使用方法 |
| AU2014200215B2 (en) * | 2008-01-31 | 2016-09-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
| CA2713281C (en) | 2008-01-31 | 2019-10-15 | Dimiter S. Dimitrov | Engineered antibody constant domain molecules |
| JP2011512877A (ja) * | 2008-03-12 | 2011-04-28 | ワイス・エルエルシー | 組換えタンパク質の大スケール産生に適した細胞を同定する方法 |
| CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
| BRPI0911377A8 (pt) | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| WO2009134738A1 (en) * | 2008-04-29 | 2009-11-05 | Genentech, Inc. | Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody |
| WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| WO2010014629A1 (en) * | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
| MX2011002273A (es) | 2008-08-28 | 2011-03-30 | Novartis Ag | Despliegue de isoformas de polipeptido en la superficie celular por ultralectura del codon de paro. |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| US20100113304A1 (en) * | 2008-09-26 | 2010-05-06 | Wyeth | Compatible display vector systems |
| WO2010036856A2 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
| KR20170091801A (ko) | 2008-10-02 | 2017-08-09 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Ｃｄ86 길항제 다중-표적 결합 단백질 |
| JP2012504970A (ja) * | 2008-10-10 | 2012-03-01 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｔｃｒ複合体免疫治療 |
| CA2741373A1 (en) | 2008-10-30 | 2010-06-03 | Peixuan Guo | Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses |
| US20100135900A1 (en) * | 2008-11-13 | 2010-06-03 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| JP2012509270A (ja) * | 2008-11-17 | 2012-04-19 | ジェネンテック， インコーポレイテッド | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
| CA2744449C (en) * | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
| BRPI1011384A2 (pt) * | 2009-02-23 | 2016-03-15 | Cytomx Therapeutics Inc | pro-proteinas e seus metodos de uso |
| RU2011137030A (ru) | 2009-03-11 | 2013-04-20 | УАЙТ ЭлЭлСи | Способы очистки малых модулярных иммунофармацевтических белков |
| JP2010213694A (ja) | 2009-03-12 | 2010-09-30 | Wyeth Llc | ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法 |
| EP2432488A4 (en) | 2009-03-20 | 2014-01-08 | Amgen Inc | SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS |
| WO2010111378A1 (en) | 2009-03-24 | 2010-09-30 | Wyeth Llc | Membrane evaporation for generating highly concentrated protein therapeutics |
| KR101470690B1 (ko) | 2009-04-10 | 2014-12-10 | 아블린쓰 엔.브이. | Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드 |
| WO2010132697A2 (en) * | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| SG176095A1 (en) | 2009-06-05 | 2011-12-29 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| US20120226119A1 (en) | 2009-07-09 | 2012-09-06 | Hoffmann-La Roche Inc. | Vivo tumor vasculature imaging |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| EP2496691B1 (en) | 2009-11-02 | 2017-02-22 | University of Washington | Therapeutic nuclease compositions and methods |
| TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP3309176B1 (en) | 2009-12-14 | 2025-10-01 | Ablynx N.V. | Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| US20130052195A1 (en) | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
| CN105693861A (zh) | 2009-12-29 | 2016-06-22 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
| BR112012020102A2 (pt) | 2010-02-10 | 2016-11-29 | Immunogen Inc | anticorpos cd20 e usos dos mesmos. |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US9260529B2 (en) | 2010-02-24 | 2016-02-16 | The University Of Washington Through Its Center For Commercialization | Molecules that bind CD180, compositions and methods of use |
| AU2011226672B2 (en) * | 2010-03-12 | 2015-07-23 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| CA2793778A1 (en) | 2010-04-05 | 2011-11-13 | Wyeth Llc | Biomarkers for p13k-driven cancer |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| MX2012013490A (es) | 2010-05-20 | 2013-01-29 | Ablynx Nv | Materiales biologicos relacionados con her3. |
| JP5980782B2 (ja) | 2010-07-30 | 2016-08-31 | ファイザー・インク | タンパク質のタンデム精製 |
| EP2600895A1 (en) | 2010-08-03 | 2013-06-12 | Hoffmann-La Roche AG | Chronic lymphocytic leukemia (cll) biomarkers |
| KR20130097747A (ko) | 2010-08-10 | 2013-09-03 | 암젠 인크 | 표적 항체에 대한 중화 항체의 검출을 위한 이중 기능 시험관내 표적 결합 분석평가 |
| SI2609118T1 (sl) | 2010-08-23 | 2017-05-31 | The Board Of Regents, The University Of Texas System | Protitelesa proti ox40 in postopki uporabe istih |
| CA2885176C (en) | 2010-09-22 | 2018-10-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| KR101650995B1 (ko) | 2010-11-08 | 2016-08-25 | 노파르티스 아게 | Ｃｘｃｒ２ 결합 폴리펩티드 |
| JP6014596B2 (ja) * | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| SI2646470T1 (sl) | 2010-11-30 | 2017-05-31 | F. Hoffmann-La Roche Ag | Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade |
| HUE031197T2 (en) | 2011-01-10 | 2017-06-28 | Ct Atlantic Ltd | Combination therapy using tumor-associated antigen-binding antigens |
| CA2827170A1 (en) | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| JP6196163B2 (ja) | 2011-03-17 | 2017-09-13 | ミネルバ バイオテクノロジーズ コーポレーション | 多能性幹細胞を作製する方法 |
| SG193447A1 (en) | 2011-04-01 | 2013-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| CA2833019A1 (en) * | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| BR112013027547B1 (pt) * | 2011-04-29 | 2021-01-19 | University Of Washington | polipeptídeo, dímero, composição, molécula de ácido nucleico, vetor de expressão recombinante, célula hospedeira microbiana, método para preparar o polipeptídeo e composição contendo nucleasse |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JP2014517690A (ja) * | 2011-05-09 | 2014-07-24 | ミネルバ バイオテクノロジーズ コーポレーション | 遺伝子操作した成長因子変異体 |
| LT2714735T (lt) | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| US20140093514A1 (en) | 2011-06-03 | 2014-04-03 | University Of Zurich | Magea3 binding antibodies |
| US20140186363A1 (en) | 2011-06-03 | 2014-07-03 | University Of Zurich | Magea3 binding antibodies |
| CN107519486B (zh) * | 2011-06-24 | 2021-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| ES2810424T3 (es) | 2011-06-30 | 2021-03-08 | Genzyme Corp | Inhibidores de la activación de células T |
| EP2726503B1 (en) | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| EP2734232B1 (en) | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
| EP2756093A4 (en) | 2012-02-01 | 2015-07-01 | Compugen Ltd | C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| UA119227C2 (uk) | 2012-04-20 | 2019-05-27 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептид, що зв'язується з cd3 |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| JP2015517511A (ja) | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| MX364738B (es) | 2012-06-15 | 2019-05-03 | Pfizer | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos. |
| JP5600758B2 (ja) * | 2013-01-23 | 2014-10-01 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
| KR20230141929A (ko) * | 2013-07-31 | 2023-10-10 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| JP2017504621A (ja) | 2013-10-02 | 2017-02-09 | ヴィヴェンティア バイオ インコーポレイテッド | 抗ｅｐｃａｍ抗体及び使用方法 |
| HRP20210410T1 (hr) | 2013-10-11 | 2021-04-30 | Oxford Bio Therapeutics Limited | Konjugirana antitijela prema ly75 za liječenje raka |
| SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| EP3068797B1 (en) | 2013-11-11 | 2020-01-08 | Wake Forest University Health Sciences | Constructs for multi-valent targeting of tumors |
| EP3077823B1 (en) | 2013-12-05 | 2019-09-04 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JP6646584B2 (ja) | 2014-01-27 | 2020-02-14 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 哺乳動物への応用のための脱免疫化された志賀毒素ａサブユニットエフェクターポリペプチド |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US11142584B2 (en) * | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP6795399B2 (ja) | 2014-03-28 | 2020-12-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| EP3560954B1 (en) | 2014-04-03 | 2021-08-04 | IGM Biosciences, Inc. | Modified j-chain |
| PT3143042T (pt) | 2014-05-16 | 2020-09-01 | Ablynx Nv | Domínios variáveis de imunoglobulina |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
| WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| JP6956631B2 (ja) | 2014-09-15 | 2021-11-02 | アムジェン インコーポレイテッド | 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用 |
| BR112017005390A2 (pt) | 2014-09-17 | 2017-12-12 | Novartis Ag | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva |
| PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| JP6849590B2 (ja) * | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
| EP3221351B1 (en) * | 2014-11-19 | 2024-11-13 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of epha2 |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
| EP3250587B1 (en) | 2015-01-29 | 2020-03-25 | Regents of the University of Minnesota | Chimeric antigen receptors, compositions, and methods |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| EP3265491A1 (en) | 2015-03-03 | 2018-01-10 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
| CA2978324A1 (en) | 2015-03-04 | 2016-09-09 | Igm Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| HK1249731A1 (zh) | 2015-03-12 | 2018-11-09 | Viventia Bio Inc. | 针对就上皮细胞黏着分子呈阳性反应的膀胱癌的剂量技巧 |
| US10167334B2 (en) | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
| DK3280432T3 (da) | 2015-04-06 | 2021-04-26 | Subdomain Llc | Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf |
| DK3280729T3 (da) | 2015-04-08 | 2022-07-25 | Novartis Ag | Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle |
| GB201506402D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| WO2016184987A1 (en) | 2015-05-19 | 2016-11-24 | Yaya Diagnostics Gmbh | Means and methods for the enrichment of nucleic acids |
| CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| CA2987877A1 (en) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T-cell receptor specific antibodies |
| JP2018517711A (ja) | 2015-06-01 | 2018-07-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | 細胞表面タンパク質に対する抗体を作製する方法 |
| US10858760B2 (en) | 2015-06-01 | 2020-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| BR112017026027A2 (pt) | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3152570A1 (en) | 2015-08-06 | 2017-04-12 | Yaya Diagnostics GmbH | Means and methods for the detection of targets |
| JP2018532693A (ja) | 2015-08-06 | 2018-11-08 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用 |
| CN108699144B (zh) | 2015-08-28 | 2022-07-19 | 德彪发姆国际有限公司 | 用于检测cd37的抗体和测定 |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| FI3355913T3 (fi) | 2015-09-30 | 2024-12-02 | Igm Biosciences Inc | Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| US11111296B2 (en) | 2015-12-14 | 2021-09-07 | The Broad Institute, Inc. | Compositions and methods for treating cardiac dysfunction |
| KR20180094977A (ko) | 2015-12-17 | 2018-08-24 | 노파르티스 아게 | c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도 |
| MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| BR112018012826A2 (pt) | 2015-12-23 | 2018-12-04 | Medigene Immunotherapies Gmbh | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| EP3405492B1 (en) | 2016-01-21 | 2020-10-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| KR102611444B1 (ko) | 2016-04-08 | 2023-12-06 | 지엘바이오, 인크. | 플렉틴-1 결합 항체 및 그의 용도 |
| PL3443096T3 (pl) | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
| KR102682118B1 (ko) | 2016-04-29 | 2024-07-08 | 주식회사유한양행 | Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도 |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| CN109790526A (zh) | 2016-07-01 | 2019-05-21 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
| WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| WO2018026748A1 (en) | 2016-08-01 | 2018-02-08 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof |
| US11259739B2 (en) * | 2016-08-12 | 2022-03-01 | Phd Preventative Health Care And Diagnostics, Inc. | Immunotherapy treatment kit and method of using the same |
| KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
| MX2019003886A (es) | 2016-10-07 | 2019-08-05 | Novartis Ag | Receptores de antigenos quimericos para el tratamiento del cancer. |
| JP7043074B2 (ja) | 2016-10-20 | 2022-03-29 | アイ－マブ バイオファーマ ユーエス リミテッド | 新規なｃｄ４７モノクローナル抗体およびこの使用 |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3538555A1 (en) | 2016-11-14 | 2019-09-18 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
| CN110177809B (zh) | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | 能够结合CD123和TCRα/β的T细胞募集多肽 |
| IL293710B2 (en) | 2016-12-07 | 2024-10-01 | Molecular Templates Inc | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| BR122020025629B1 (pt) | 2016-12-15 | 2022-05-31 | Abbvie Biotherapeutics Inc | Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo |
| CN116970059A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| WO2018120842A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| US20200024312A1 (en) | 2017-01-25 | 2020-01-23 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| PE20200717A1 (es) | 2017-06-22 | 2020-07-21 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas |
| EP3645037A1 (en) | 2017-06-27 | 2020-05-06 | Novartis AG | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| KR20240147708A (ko) | 2017-07-11 | 2024-10-08 | 콤파스 테라퓨틱스 엘엘씨 | 인간 cd137에 결합하는 작동자 항체 및 이의 용도 |
| KR20200031659A (ko) | 2017-07-20 | 2020-03-24 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
| KR102777015B1 (ko) | 2017-08-22 | 2025-03-10 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
| JP7379347B2 (ja) * | 2017-10-11 | 2023-11-14 | ジィールバイオ，インコーポレーテッド | プレクチン１結合抗体およびその使用 |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| AU2018369639C1 (en) | 2017-11-14 | 2025-04-03 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| CN109957017A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向ox40的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957022A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向ox40的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019135668A1 (ko) | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| AU2019215031B2 (en) | 2018-01-31 | 2025-10-09 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| JP2021514656A (ja) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| MX2019009726A (es) | 2018-04-17 | 2020-02-05 | Molecular Templates Inc | Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados. |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| US20200109195A1 (en) | 2018-05-21 | 2020-04-09 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| JP2021525735A (ja) | 2018-05-30 | 2021-09-27 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７免疫コンジュゲート投薬レジメン |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
| CA3104295A1 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| ES2985387T3 (es) | 2018-09-17 | 2024-11-05 | Gi Innovation Inc | Proteína de fusión que comprende proteína IL-2 y proteína CD80, y uso de las mismas |
| JP7497351B2 (ja) | 2018-11-13 | 2024-06-10 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
| GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| JP2022513255A (ja) | 2018-12-20 | 2022-02-07 | ノバルティス アーゲー | ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用 |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021013337A2 (pt) | 2019-01-07 | 2021-11-09 | Bactolife Aps | Proteínas de ligação a patógenos |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| WO2020193718A1 (en) * | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| SG11202110732XA (en) | 2019-03-29 | 2021-10-28 | Atarga Llc | Anti fgf23 antibody |
| CN113939534B (zh) | 2019-04-03 | 2025-02-28 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| MX2021014534A (es) | 2019-05-30 | 2022-02-11 | Amgen Inc | Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos. |
| AU2020301529A1 (en) | 2019-06-24 | 2022-01-06 | Universität Stuttgart | TNFR2 agonists with improved stability |
| JP7756001B2 (ja) | 2019-06-28 | 2025-10-17 | アムジエン・インコーポレーテツド | 抗ｃｇｒｐ受容体／抗ｐａｃ１受容体二重特異性抗原結合タンパク質 |
| GB201910900D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
| MX2022001882A (es) | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| EP4034244A1 (en) * | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Binding modules comprising modified ehd2 domains |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
| WO2021091906A1 (en) | 2019-11-04 | 2021-05-14 | Amgen Inc. | Methods for treating leukemia |
| MX2022006391A (es) | 2019-11-26 | 2022-06-24 | Novartis Ag | Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos. |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4090762A1 (en) | 2020-01-17 | 2022-11-23 | Becton, Dickinson and Company | Methods and compositions for single cell secretomics |
| CA3167413A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| BR112022016633A2 (pt) | 2020-02-27 | 2022-12-13 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| JP2023531141A (ja) * | 2020-05-21 | 2023-07-21 | ザイダス・ライフサイエンシーズ・リミテッド | Ｆｃバリアント及びその調製 |
| WO2021257329A1 (en) * | 2020-06-19 | 2021-12-23 | Iowa State University Research Foundation, Inc. | Nanoscale polymeric micellar scaffolds for rapid and efficient antibody production |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| PE20231093A1 (es) | 2020-07-16 | 2023-07-18 | Novartis Ag | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
| CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| WO2022078466A1 (en) * | 2020-10-14 | 2022-04-21 | I-Mab Biopharma Co., Ltd. | Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assays |
| US20240002509A1 (en) | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| JP2023549504A (ja) | 2020-11-13 | 2023-11-27 | ノバルティス アーゲー | キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法 |
| WO2022119976A1 (en) | 2020-12-01 | 2022-06-09 | Aptevo Research And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| CA3209052A1 (en) | 2021-02-19 | 2022-08-25 | Rafael Cristian CASELLAS | Single domain antibodies that neutralize sars-cov-2 |
| CN113512109B (zh) * | 2021-03-09 | 2022-03-25 | 北京康乐卫士生物技术股份有限公司 | 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US20240182600A1 (en) | 2021-04-20 | 2024-06-06 | Amgen Inc. | Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly |
| WO2022232376A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CA3224182A1 (en) * | 2021-06-17 | 2022-12-22 | Fapon Biotech Inc. | Chimeric immunoglobulin |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4405398A4 (en) | 2021-09-21 | 2025-10-29 | Qilu Puget Sound Biotherapeutics Corp | FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES |
| AU2022366971A1 (en) | 2021-10-14 | 2024-05-02 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| US20230383010A1 (en) | 2022-02-07 | 2023-11-30 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
| CN115286701A (zh) * | 2022-03-07 | 2022-11-04 | 江苏靶标生物医药研究所有限公司 | 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用 |
| JP2025509892A (ja) | 2022-03-21 | 2025-04-11 | アムジェン インコーポレイテッド | 前立腺癌の治療のためのｔ細胞エンゲージ分子を用いた併用療法 |
| CN114591988B (zh) * | 2022-03-30 | 2023-01-13 | 北京贝来生物科技有限公司 | 一种激活肿瘤免疫的基因修饰干细胞制备方法 |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| WO2024049684A1 (en) | 2022-08-30 | 2024-03-07 | Amgen Inc. | Live cell profiling assay |
| JP2025529258A (ja) | 2022-09-06 | 2025-09-04 | アムジェン インコーポレイテッド | リーン灌流細胞培養法 |
| JP2025535042A (ja) | 2022-10-05 | 2025-10-22 | アムジェン インコーポレイテッド | Ｔ細胞リダイレクト療法及びアゴニスト抗ｉｌ－２ｒ抗体又はその断片を含む組み合わせ療法 |
| EP4605077A1 (en) | 2022-10-18 | 2025-08-27 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2024163713A1 (en) | 2023-02-02 | 2024-08-08 | Amgen Inc. | Mitigation of therapeutic protein fragmentation during cell culture harvest processes |
| WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
| CN121079323A (zh) | 2023-02-21 | 2025-12-05 | 特尼奥生物股份有限公司 | c-Kit结合蛋白、嵌合抗原受体及其用途 |
| CN120826269A (zh) | 2023-03-13 | 2025-10-21 | 安进公司 | 使用超大病毒预过滤器的病毒过滤操作 |
| TW202500572A (zh) | 2023-03-14 | 2025-01-01 | 美商安進公司 | 使用一級胺配體的陰離子交換層析製程 |
| WO2024263504A2 (en) | 2023-06-20 | 2024-12-26 | Amgen Inc. | Methods for chromatography and chromatography medium reuse |
| TW202540169A (zh) | 2023-11-08 | 2025-10-16 | 法商賽諾菲公司 | 基於ｃｄ２５的溶酶體降解物及其用途 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025160161A1 (en) | 2024-01-23 | 2025-07-31 | Amgen Inc. | Methods for modulating monoclonal antibody charge variants |
| WO2025160446A1 (en) * | 2024-01-25 | 2025-07-31 | Ai Proteins, Inc. | Methods and systems for characterizing structural features of a protein |
| WO2025184315A1 (en) | 2024-02-29 | 2025-09-04 | Amgen Inc. | Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies |
| WO2025193791A1 (en) | 2024-03-14 | 2025-09-18 | Amgen Inc. | Intensified ultrafiltration/diafiltration processes |
| WO2025217101A2 (en) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Agonistic anti-il-2rbg heavy‑chain antibodies |
| EP4635980A1 (en) | 2024-04-19 | 2025-10-22 | Medigene Immunotherapies GmbH | Uni-tags specific antibody |
| WO2025251034A1 (en) | 2024-05-31 | 2025-12-04 | Amgen Inc. | Purification method |
Family Cites Families (226)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| BE563332A (is) | 1956-12-20 | |||
| US3046301A (en) | 1959-10-29 | 1962-07-24 | Burroughs Wellcome Co | Method of making chlorambucil |
| US3732340A (en) | 1966-07-11 | 1973-05-08 | Asta Werke Ag Chem Fab | N',o-propylene phosphoric acid ester diamides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3923785A (en) | 1974-04-22 | 1975-12-02 | Parke Davis & Co | (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol |
| US4080325A (en) | 1976-11-17 | 1978-03-21 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of methotrexate |
| US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| NZ201418A (en) | 1982-07-28 | 1986-08-08 | Barmac Ass Ltd | Mineral breaker with centrifugal breaking action |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5175269A (en) | 1984-01-30 | 1992-12-29 | Enzo Diagnostics, Inc. | Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5118627A (en) | 1984-02-27 | 1992-06-02 | Amgen | Papova virus construction |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5212286A (en) | 1984-04-19 | 1993-05-18 | Scios Nova Inc. | Atrial natriuretic/vasodilator peptide compounds |
| US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
| US4935495A (en) * | 1984-12-21 | 1990-06-19 | Oncogen | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas |
| US4906562A (en) * | 1984-12-21 | 1990-03-06 | Oncogen | Monocolonal antibodies and antigen for human non-small cell lung carcinomas |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5656266A (en) * | 1985-11-19 | 1997-08-12 | Schering Corporation | Method of using interleukin-4 |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6121424A (en) * | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5220013A (en) | 1986-11-17 | 1993-06-15 | Scios Nova Inc. | DNA sequence useful for the detection of Alzheimer's disease |
| US5187153A (en) | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5229279A (en) | 1987-06-29 | 1993-07-20 | Massachusetts Institute Of Technology | Method for producing novel polyester biopolymers |
| US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5223483A (en) | 1987-10-22 | 1993-06-29 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| FI102355B1 (fi) * | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5098833A (en) * | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
| US5215907A (en) | 1989-02-24 | 1993-06-01 | Oklahoma Medical Research Foundation | Thermostable acid protease from sulfolobus acidocaldarius |
| US5173403A (en) | 1989-02-24 | 1992-12-22 | Oklahoma Medical Research Foundation | Thermostable acid protease from sulfolobus acidocaldarius and gene |
| US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5897861A (en) * | 1989-06-29 | 1999-04-27 | Medarex, Inc. | Bispecific reagents for AIDS therapy |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| EP0845537A1 (en) | 1989-08-18 | 1998-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5218088A (en) | 1989-11-02 | 1993-06-08 | Purdue Research Foundation | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| JPH05503015A (ja) | 1990-02-28 | 1993-05-27 | シェリング・コーポレーション | 哺乳類発現ベクター |
| KR920003787B1 (ko) | 1990-03-05 | 1992-05-14 | 한국과학기술 연구원 | 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법 |
| US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US20030219446A1 (en) * | 1990-03-26 | 2003-11-27 | Bristol-Myers Squibb Company | Ligand for CD28 receptor on B cells and methods |
| US5212058A (en) | 1990-05-09 | 1993-05-18 | Massachusetts Institute Of Technology | Nucleic acid encoding ubiquitin-specific proteases |
| US5122463A (en) | 1990-05-17 | 1992-06-16 | Massachusetts Institute Of Technology | Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor |
| DE4017595A1 (de) | 1990-05-31 | 1991-12-05 | Consortium Elektrochem Ind | Maltopentaose produzierende amylasen |
| JPH06508501A (ja) | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
| US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
| US5266317A (en) | 1990-10-04 | 1993-11-30 | University Of Georgia Research Foundation, Inc. | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions |
| US6099842A (en) | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
| US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| AU651228B2 (en) | 1991-05-31 | 1994-07-14 | Genentech Inc. | Treatment of HIV-associated immune thrombocytopenic purpura |
| CA2110518C (en) | 1991-06-27 | 2007-05-22 | Peter S. Linsley | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| WO1993003709A1 (en) | 1991-08-16 | 1993-03-04 | Vical, Inc. | Composition and method for treating cystic fibrosis |
| US5243041A (en) | 1991-08-22 | 1993-09-07 | Fernandez Pol Jose A | DNA vector with isolated CDNA gene encoding metallopanstimulin |
| US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ATE297465T1 (de) * | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ES2341666T3 (es) * | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US6472510B1 (en) * | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
| US5596090A (en) | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69327620T2 (de) | 1992-08-18 | 2000-08-03 | Centro De Immunologia Molecular, Ciudad De La Habana | Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen |
| PT1589107E (pt) * | 1992-08-21 | 2010-03-29 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| PL174721B1 (pl) * | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6482919B2 (en) * | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5597707A (en) * | 1993-04-15 | 1997-01-28 | Bristol-Myers Squibb Company | Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use |
| US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
| US5747654A (en) * | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5571711A (en) | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
| NZ549136A (en) * | 1993-09-02 | 2008-02-29 | Dartmouth College | Products for inducing antigen-specific T cell tolerance |
| US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US6380369B1 (en) * | 1994-01-27 | 2002-04-30 | Human Genome Sciences, Inc. | Human DNA mismatch repair proteins |
| DE69521789T2 (de) * | 1994-02-01 | 2002-04-25 | The United States Of Amerika Represented By The Secretary, Department Of Health And Human | Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten |
| DE69533295T3 (de) | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
| ATE232902T1 (de) * | 1994-03-17 | 2003-03-15 | Merck Patent Gmbh | Anti-egfr einkettige fvs und anti-egfr antikoerper |
| US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| ES2153045T3 (es) | 1994-08-26 | 2001-02-16 | Aventis Pharma Gmbh | Terapia genica de enfermedades condicionadas por el sistema inmunologico, con ayuda de una sustancia activa especifica de la celula y regulada por el ciclo celular. |
| US6380169B1 (en) * | 1994-08-31 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Metal complex containing oligonucleoside cleavage compounds and therapies |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| EP0739981A1 (en) * | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
| JPH0975090A (ja) | 1995-09-13 | 1997-03-25 | Kanegafuchi Chem Ind Co Ltd | 細胞付着部材 |
| DE69629580D1 (de) * | 1995-10-13 | 2003-09-25 | Us Gov Health & Human Serv | Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment |
| US6379966B2 (en) * | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| JP4751493B2 (ja) * | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
| EP1186300A1 (en) | 1996-03-20 | 2002-03-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
| NZ333325A (en) * | 1996-07-12 | 2000-06-23 | Genentech Inc | Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors |
| DE69726003T2 (de) * | 1996-07-16 | 2004-08-26 | Andreas Plückthun | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
| GB9618477D0 (en) * | 1996-09-04 | 1996-10-16 | Univ Leeds | Gene therapy |
| US6193963B1 (en) * | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
| US5858753A (en) * | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| DE19651443A1 (de) | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| JP3718023B2 (ja) * | 1997-02-12 | 2005-11-16 | 富士写真フイルム株式会社 | 画像形成方法 |
| EP0860445A1 (en) * | 1997-02-18 | 1998-08-26 | Hoechst Aktiengesellschaft | New nucleotide sequences for the cell cycle regulated expression of structural genes |
| CA2284211A1 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US6383746B1 (en) | 1997-10-23 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Functional promoter for CCR5 |
| US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
| WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6284536B1 (en) * | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
| EE200000605A (et) | 1998-04-22 | 2002-04-15 | Genvec, Inc. | Adenoviiruse efektiivne puhastamine |
| WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| WO2000011149A1 (en) | 1998-08-24 | 2000-03-02 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
| AU2472400A (en) * | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6197294B1 (en) * | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6380371B1 (en) * | 1998-12-10 | 2002-04-30 | The Regents Of The University Of California | Endoglycan: a novel protein having selectin ligand and chemokine presentation activity |
| WO2000044777A1 (en) | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
| US6383753B1 (en) | 1999-03-31 | 2002-05-07 | Regents Of The University Of Michigan | Yeast mammalian regulators of cell proliferation |
| GB9909925D0 (en) | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| EP2289551A1 (en) * | 1999-06-09 | 2011-03-02 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US6380362B1 (en) * | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| CN1441677A (zh) * | 2000-03-31 | 2003-09-10 | Idec药物公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| MXPA02010011A (es) * | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| US6518277B1 (en) * | 2000-04-25 | 2003-02-11 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| EP2052742A1 (en) * | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| SI1296714T1 (sl) * | 2000-06-22 | 2010-01-29 | S For Entpr University Of Iowa | Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka |
| AU2001287537A1 (en) * | 2000-08-11 | 2002-02-25 | Ruprecht-Karls-Universitat Heidelberg | Fv constructs with an influenceable affinity for substance that is to be linked |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| BR0207854A (pt) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
| US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
| EP1519959B1 (en) | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US8361464B2 (en) * | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
| KR20040088572A (ko) * | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | 제거율 증강을 위한 양특이성 항체 점 돌연변이들 |
| US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| ES2354610T5 (es) * | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
| US6864837B2 (en) * | 2003-07-18 | 2005-03-08 | Ems Technologies, Inc. | Vertical electrical downtilt antenna |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| MXPA05007210A (es) * | 2003-11-13 | 2006-02-10 | Hanmi Pharm Ind Co Ltd | Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo. |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| US8034902B2 (en) * | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
| BRPI0614183A2 (pt) * | 2005-07-25 | 2011-03-15 | Trubion Pharmaceuticals Inc | uso de dose única de moléculas de ligação especìficas para cd20 |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| WO2007014278A2 (en) * | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| JP5405831B2 (ja) * | 2005-12-20 | 2014-02-05 | モルフォシス アーゲー | Ｈ−ｃｄｒ３領域の新規集合体およびその使用 |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| US7846434B2 (en) * | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| BRPI0814060A2 (pt) * | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
| BRPI0911377A8 (pt) * | 2008-04-11 | 2017-12-05 | Trubion Pharmaceuticals Inc | Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste |
| US20100135900A1 (en) * | 2008-11-13 | 2010-06-03 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
-
2003
- 2003-07-26 US US10/627,556 patent/US7829084B2/en not_active Expired - Fee Related
- 2003-12-24 WO PCT/US2003/041600 patent/WO2005017148A1/en not_active Ceased
- 2003-12-24 AU AU2003300092A patent/AU2003300092B2/en not_active Ceased
- 2003-12-24 CN CN2012100806998A patent/CN102643344A/zh active Pending
- 2003-12-24 RS YUP-2006/0055A patent/RS20060055A/sr unknown
- 2003-12-24 NZ NZ545316A patent/NZ545316A/xx not_active IP Right Cessation
- 2003-12-24 HR HR20060074A patent/HRP20060074A2/xx not_active Application Discontinuation
- 2003-12-24 KR KR1020067001895A patent/KR101163240B1/ko not_active Expired - Fee Related
- 2003-12-24 AT AT03800349T patent/ATE525399T1/de not_active IP Right Cessation
- 2003-12-24 JP JP2005507945A patent/JP4904443B2/ja not_active Expired - Fee Related
- 2003-12-24 CN CN2003801104703A patent/CN1852976B/zh not_active Expired - Fee Related
- 2003-12-24 UA UAA200602043A patent/UA90999C2/ru unknown
- 2003-12-24 ES ES03800349T patent/ES2376751T3/es not_active Expired - Lifetime
- 2003-12-24 EA EA200600313A patent/EA200600313A1/ru unknown
- 2003-12-24 CA CA002533921A patent/CA2533921A1/en not_active Abandoned
- 2003-12-24 PL PL381765A patent/PL381765A1/pl unknown
- 2003-12-24 BR BRPI0318417-0A patent/BR0318417A/pt not_active IP Right Cessation
- 2003-12-24 AP AP2006003527A patent/AP2006003527A0/xx unknown
- 2003-12-24 EP EP03800349A patent/EP1654358B1/en not_active Expired - Lifetime
-
2006
- 2006-01-24 IL IL173322A patent/IL173322A0/en unknown
- 2006-01-26 TN TNP2006000029A patent/TNSN06029A1/en unknown
- 2006-02-16 IS IS8305A patent/IS8305A/is unknown
- 2006-02-17 NO NO20060764A patent/NO20060764L/no not_active Application Discontinuation
- 2006-02-23 CR CR8257A patent/CR8257A/es not_active Application Discontinuation
- 2006-02-24 ZA ZA200601653A patent/ZA200601653B/xx unknown
-
2009
- 2009-02-13 US US12/371,467 patent/US20090196870A1/en not_active Abandoned
-
2010
- 2010-07-12 US US12/834,707 patent/US20100279932A1/en not_active Abandoned
- 2010-09-10 JP JP2010203772A patent/JP2010279389A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060764L (no) | Bindingskonstruksjoner og fregangsmater for andvendelse derav | |
| WO2005037989A3 (en) | Binding domain-immunoglobulin fusion proteins | |
| Ruggiero et al. | Triple helix assembly and processing of human collagen produced in transgenic tobacco plants | |
| TWI578998B (zh) | 抗ｉｌ－６受體的抗體 | |
| Cagan | Chemostimulatory Protein: A New Type of Taste Stimulus: Two proteins that taste sweet are now known. | |
| Lightle et al. | Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding | |
| Van Buren et al. | Elucidation of two major aggregation pathways in an IgG2 antibody | |
| RU2003129528A (ru) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела | |
| WO2004042017A3 (en) | Methods and compositions for increasing antibody production | |
| MX2009012319A (es) | Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. | |
| CA2433877A1 (en) | Binding domain-immunoglobulin fusion proteins | |
| JP2017512063A5 (is) | ||
| MXPA02010670A (es) | Nuevas moleculas co-estimuladoras de celula dendritica. | |
| WO2005056600B1 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| WO1999006544A8 (en) | Membrane-bound cytokine compositions and methods of modulating an immune response using same | |
| RU2008110050A (ru) | СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ | |
| Ghirlando et al. | Stoichiometry and thermodynamics of the interaction between the Fc fragment of human IgG1 and its low-affinity receptor Fc. gamma. RIII | |
| Collarini et al. | Gating processes of channels induced by colicin A, its C-terminal fragment and colicin E1 in planar lipid bilayers | |
| NO20061081L (no) | Nogo-reseptorentagonister | |
| WO2002060951A3 (en) | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii | |
| CA2390082A1 (en) | Novel hcv non-structural polypeptide | |
| WO2003088995A3 (en) | Mucin fusion polypeptide vaccines, compositions and methods of use thereof | |
| WO1999050424A3 (en) | Fusion protein comprising a sequence from a major coat protein of a papovavirus | |
| Kass | Sodium Channel Inactivation in Heart: A Novel Role of the Carboxy‐Terminal Domain | |
| WO2007051063A3 (en) | Gpcr expressing cell lines and antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |